The Association of an Alpha-2 Adrenergic Receptor Agonist and Mortality in Patients With COVID-19.

ABSTRACT: There is a need for treatments to reduce coronavirus disease 2019 (COVID-19) mortality. Alpha-2 adrenergic receptor (α₂ AR) agonists can dampen immune cell and inflammatory responses as well as improve oxygenation through physiologic respiratory parameters. Therefore, α₂ AR agonists may be effective in reducing mortality related to hyperinflammation and acute respiratory failure in COVID-19. Dexmedetomidine (DEX) is an α₂ AR agonist used for sedation. We performed a retrospective analysis of adults at Rush University System for Health hospitals between March 1, 2020 and July 30, 2020 with COVID-19 requiring invasive mechanical ventilation and sedation (n = 214). We evaluated the association of DEX use and 28-day mortality from time of intubation. Ove

SUBMITTER: Hamilton JL 

PROVIDER: S-EPMC8764306 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature